Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reaffirmed at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating restated by analysts at Chardan Capital in a research report issued on Thursday, Benzinga reports. They presently have a $115.00 target price on the biotechnology company’s stock. Chardan Capital’s price objective suggests a potential upside of 96.72% from the company’s previous close.

Other analysts have also issued reports about the stock. Citigroup assumed coverage on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 8th. They set a “buy” rating and a $108.00 price target on the stock. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They issued a “buy” rating and a $98.00 target price on the stock. HC Wainwright reiterated a “buy” rating and issued a $120.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday. Leerink Partners lifted their price target on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Finally, The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a research report on Thursday, September 24th. They set a “neutral” rating and a $74.00 price target on the stock. Eleven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $99.07.

Arrowhead Pharmaceuticals Stock Up 0.2%

ARWR traded up $0.09 during trading on Thursday, reaching $58.46. The company had a trading volume of 866,926 shares, compared to its average volume of 2,286,365. The business’s fifty day moving average price is $76.71 and its 200 day moving average price is $75.99. The company has a debt-to-equity ratio of 1.77, a current ratio of 5.90 and a quick ratio of 5.90. Arrowhead Pharmaceuticals has a 12 month low of $36.57 and a 12 month high of $95.49. The company has a market cap of $8.23 billion, a P/E ratio of -25.95 and a beta of 1.29.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.13). The business had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. Arrowhead Pharmaceuticals’s revenue for the quarter was up 171.0% on a year-over-year basis. During the same quarter last year, the business earned ($1.26) earnings per share. Equities analysts anticipate that Arrowhead Pharmaceuticals will post -3.62 EPS for the current year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Adeoye Y. Olukotun sold 2,000 shares of the company’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $86.96, for a total value of $173,920.00. Following the transaction, the director directly owned 31,600 shares of the company’s stock, valued at $2,747,936. This represents a 5.95% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Michael S. Perry sold 11,600 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the sale, the director owned 111,459 shares of the company’s stock, valued at approximately $9,730,370.70. This trade represents a 9.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 3.60% of the company’s stock.

Institutional Trading of Arrowhead Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ARWR. Assenagon Asset Management S.A. increased its position in Arrowhead Pharmaceuticals by 243.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 201,927 shares of the biotechnology company’s stock valued at $16,459,000 after purchasing an additional 143,192 shares during the period. Squarepoint Ops LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the 2nd quarter worth $20,859,000. Siren L.L.C. lifted its holdings in Arrowhead Pharmaceuticals by 7.7% during the first quarter. Siren L.L.C. now owns 1,615,476 shares of the biotechnology company’s stock worth $101,290,000 after acquiring an additional 115,000 shares during the period. Corient Private Wealth LP bought a new stake in Arrowhead Pharmaceuticals in the second quarter worth about $1,313,000. Finally, Empowered Funds LLC lifted its stake in Arrowhead Pharmaceuticals by 661.6% in the first quarter. Empowered Funds LLC now owns 137,220 shares of the biotechnology company’s stock valued at $8,604,000 after purchasing an additional 119,202 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Positive ARO-MAPT results: Interim Phase 1/2a data showed up to a 73% reduction in tau, a protein associated with Alzheimer’s disease, with reductions described as deep and durable in healthy volunteers. The company said the results provide the first clinical validation of its TRiM platform’s ability to deliver siRNA across the blood-brain barrier and reduce a target gene in the brain. Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data
• Positive Sentiment: Alzheimer’s program strengthens the pipeline: The reported ability to cross the blood-brain barrier could support ARO-MAPT and other programs using Arrowhead’s TRiM CNS delivery platform. Coverage highlighted the potential significance of the early-stage data, although the study remains investigational and was conducted in healthy volunteers. Arrowhead Reports Positive Phase 1/2a Data for Alzheimer’s Candidate ARO-MAPT
• Positive Sentiment: Analysts reaffirm bullish views: Chardan Capital reiterated its “buy” rating and set a $115 price target, while HC Wainwright also reaffirmed “buy” with a $120 target. Both targets imply substantial upside from recent trading levels, providing additional support for investor sentiment.
• Neutral Sentiment: Important clinical caveat: The ARO-MAPT findings are interim Phase 1/2a results and primarily demonstrate biomarker reduction and delivery, not yet proof that the therapy improves cognition or slows Alzheimer’s disease. Further clinical testing will be needed to establish efficacy and safety. Arrowhead Discusses ARO-MAPT Interim Results and TRiM CNS Delivery
• Neutral Sentiment: Some coverage noted differing analyst views on healthcare stocks, including Arrowhead, indicating that valuation and execution risks remain despite the favorable ARO-MAPT update.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. Its research is based primarily on RNA interference (RNAi), a biological process that reduces the production of specific proteins by targeting messenger RNA before it can be used to make those proteins.

The company uses its proprietary Targeted RNAi Molecule (TRiM) platform to design and deliver RNAi therapeutics to selected tissues, including the liver and lungs.